Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22079874 | 0.82 | ALDH1A1 (0.51) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL12527554 | 0.79 | KLKB1 (0.43) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL12526833 | 0.79 | KDM4E (0.39) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL18123592 | 0.78 | KDM4E (0.38) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL18123831 | 0.78 | KDM4E (0.38) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL18123699 | 0.77 | MAPT (0.37) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL18123783 | 0.77 | MAPT (0.37) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL28661959 | 0.76 | ALDH1A1 (0.41) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL20851793 | 0.76 | LMNA (0.43) | KDM4EMAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL15200611 | 0.76 | ALOX15 (0.41) | KDM4EMAPTALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311969-B | Novel compounds and compositions for targeting cancer stem cells | 北京强新生物科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-104080449-A | Method for preparing aqueous mano particle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD | 2014-10-01 | — | — | CN | claimed |
| CN-107721958-B | Novel compounds and compositions for targeting cancer stem cells | 北京强新生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-2547205-B1 | NOVEL METHODS FOR TARGETING CANCER STEM CELLS | 1GLOBE BIOMEDICAL CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-107375260-B | Novel compounds and compositions for targeting cancer stem cells | 北京强新生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-107311969-B | Novel compounds and compositions for targeting cancer stem cells | 北京强新生物科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-106211758-B | Use of 2-acetylnaphtho [2,3-b ] furan-4, 9-dione for treating cancer | 北京强新生物科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-20200397740-A1 | 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER | Sumitomo Dainnipon Pharma Oncology. Inc. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10543189-B2 | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20150183756-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | BOSTON BIOMEDICAL, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150164794-A1 | METHOD FOR PREPARING AQUEOUS NANOPARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals, Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150164794-A1 | METHOD FOR PREPARING AQUEOUS NANOPARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals, Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2814480-A1 | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. (CN) | 2014-12-24 | — | — | EP | disclosed |
| CN-104080449-A | Method for preparing aqueous mano particle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD | 2014-10-01 | — | — | CN | disclosed |
| WO-2013120229-A1 | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013120229-A1 | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-08-22 | — | — | WO | disclosed |
| US-20130034591-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | BOSTON BIOMEDICAL, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130028944-A1 | NOVEL METHODS FOR TARGETING CANCER STEM CELLS | BOSTON BIOMEDICAL, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034591-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | MCL1, DDX21, TP53 | KDM4E 4028/4885MAPT 2203/4885ALDH1A1 259/4885 |
| US-20130028944-A1 | NOVEL METHODS FOR TARGETING CANCER STEM CELLS | DDX21, MCL1, SNX2 | KDM4E 4089/4885MAPT 2925/4885ALDH1A1 173/4885 |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | KDM4E 3479/4885MAPT 4840/4885ALDH1A1 716/4885 |
| US-20150164794-A1 | METHOD FOR PREPARING AQUEOUS NANOPARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS | FASN, NCDN, NCL | KDM4E 3672/4885MAPT 1903/4885ALDH1A1 114/4885 |
| US-20200397740-A1 | 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER | B3GNT2, NAT1, NQO1 | KDM4E 3905/4885MAPT 2559/4885ALDH1A1 65/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | KDM4E 3479/4885MAPT 4840/4885ALDH1A1 716/4885 |
| US-20150183756-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | MCL1, DDX21, TP53 | KDM4E 4028/4885MAPT 2203/4885ALDH1A1 259/4885 |
| US-10543189-B2 | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer | B3GNT2, NAT1, NQO1 | KDM4E 3905/4885MAPT 2559/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.